Fiche centre
Leids Universitair Medisch Centrum
Leiden — Netherlands
Essais liés13clinical trials
VilleLeidenlocalisation
PaysNetherlandslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05152147
Essais cliniques associés
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Zanidatamab | Parkinson | Phase 3 | NCT05152147 | HERIZON-GEA-01 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | ACTIVE_NOT_RECRUITING |
| BMN 351 | Myopathies | Phase 1/2 | NCT06280209 | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT07678775 | Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 | ACTIVE_NOT_RECRUITING |
| ENTR-601-44 | Myopathies | Phase 2 | NCT07682129 | Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | NOT_YET_RECRUITING |
| Empasiprubart IV | Myasthénie | Phase 2 | NCT07673627 | ADAPT Forward2 — ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis | RECRUITING |
| BMN 351 | Myopathies | Phase 2 | NCT07573631 | An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| ENTR-601-45 | Myopathies | Phase 1/2 | NCT07038824 | ELEVATE-45 — A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | RECRUITING |
| Efgartigimod IV or Efgartigimod PH20 SC | Myasthénie | Phase 2/3 | NCT05374590 | ADAPT Jr + — Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | ENROLLING_BY_INVITATION |
| Efgartigimod IV | Myasthénie | Phase 2/3 | NCT04833894 | ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |